According to a research paper published online today in the journal Nature, a team of scientists from multiple countries has discovered 21 existing drugs that can prevent the replication of SARS-CoV-2 through a large-scale screening of more than 12,000 small molecules.
the work was led by Professor Sumit Chanda of the Sanford Burnham Prebys Medical Discovery Institute.
scientists used high-volume screening to identify compounds in the ReFRAME drug reuse library that have been approved by the FDA for use in other diseases or have under extensive human safety testing.
whether these small molecular compounds have the ability to block the replication of new corona viruses, the researchers found that 100 drug molecules had antiviral activity in laboratory tests, 21 of which were effective at safe doses.
noteworthy that four of these compounds are in synergy with the current standard treatment drug remdesivir.
previous clinical studies, Redsiever has been shown to shorten recovery time in hospitalized patients, but the drug is not effective for all patients on medication.
Chanda said: "The priority remains to find effective, ready-made medicines that are available to patients, to supplement Redsiever, or to give preventive medication to outpatients with signs of infection.
" In this study, the team conducted extensive testing and validation studies, including evaluating the drug in the human lung biopsy tissue infected with the virus, evaluating the synergy between the drug and Redsivir, and establishing a dose-response relationship between the drug and antiviral activity.
Of the 21 drugs that effectively block virus replication, the scientists found that 13 had previously entered clinical trials of other adaptive disorders and had the potential to be effective in patients with COVID-19 at safe doses; Professor
Chanda said: "Based on our current analysis, clofazamine, hanfangchin A, apilimod (treatment of autoimmune diseases) and ONO5334 (potential drugs for osteoporosis) are the best near-term options for the treatment of COVID-19.
Although some drugs are in the clinical trial phase of COVID-19, we believe it is important to seek additional drug candidates because if SARS-CoV-2 is resistant, we will have a variety of treatment options.
study significantly expands possible treatment options for COVID-19 patients, especially since many drug molecules already have clinical safety data in humans.
this provides the scientific community with a larger pool of potential therapeutic drugs.
," Added Professor Chanda.
researchers are currently testing all 21 compounds in animal models and "mini-lungs" that simulate human tissue, or human lung organs.
the results are positive, the team said it will discuss with the FDA a follow-up clinical trial to assess the effectiveness of these drugs, COVID-19.
: s1 Laura Riva et al., (2020) Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. Doi: Nature study identifies 21 existing drugs can treat COVID-19. Retrieved 2020-07-25, from.